Cargando…
Coronavirus vaccine development: from SARS and MERS to COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to con...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ https://www.ncbi.nlm.nih.gov/pubmed/33341119 http://dx.doi.org/10.1186/s12929-020-00695-2 |
_version_ | 1783625375596675072 |
---|---|
author | Li, Yen-Der Chi, Wei-Yu Su, Jun-Han Ferrall, Louise Hung, Chien-Fu Wu, T.-C. |
author_facet | Li, Yen-Der Chi, Wei-Yu Su, Jun-Han Ferrall, Louise Hung, Chien-Fu Wu, T.-C. |
author_sort | Li, Yen-Der |
collection | PubMed |
description | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outline the essential coronavirus biological characteristics that are important for vaccine design. In addition, we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlighting the pros and cons of each immunization strategy. Finally, based on these prior vaccination experiences, we discuss recent progress and potential challenges of COVID-19 vaccine development. |
format | Online Article Text |
id | pubmed-7749790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77497902020-12-21 Coronavirus vaccine development: from SARS and MERS to COVID-19 Li, Yen-Der Chi, Wei-Yu Su, Jun-Han Ferrall, Louise Hung, Chien-Fu Wu, T.-C. J Biomed Sci Review Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outline the essential coronavirus biological characteristics that are important for vaccine design. In addition, we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlighting the pros and cons of each immunization strategy. Finally, based on these prior vaccination experiences, we discuss recent progress and potential challenges of COVID-19 vaccine development. BioMed Central 2020-12-20 /pmc/articles/PMC7749790/ /pubmed/33341119 http://dx.doi.org/10.1186/s12929-020-00695-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Li, Yen-Der Chi, Wei-Yu Su, Jun-Han Ferrall, Louise Hung, Chien-Fu Wu, T.-C. Coronavirus vaccine development: from SARS and MERS to COVID-19 |
title | Coronavirus vaccine development: from SARS and MERS to COVID-19 |
title_full | Coronavirus vaccine development: from SARS and MERS to COVID-19 |
title_fullStr | Coronavirus vaccine development: from SARS and MERS to COVID-19 |
title_full_unstemmed | Coronavirus vaccine development: from SARS and MERS to COVID-19 |
title_short | Coronavirus vaccine development: from SARS and MERS to COVID-19 |
title_sort | coronavirus vaccine development: from sars and mers to covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ https://www.ncbi.nlm.nih.gov/pubmed/33341119 http://dx.doi.org/10.1186/s12929-020-00695-2 |
work_keys_str_mv | AT liyender coronavirusvaccinedevelopmentfromsarsandmerstocovid19 AT chiweiyu coronavirusvaccinedevelopmentfromsarsandmerstocovid19 AT sujunhan coronavirusvaccinedevelopmentfromsarsandmerstocovid19 AT ferralllouise coronavirusvaccinedevelopmentfromsarsandmerstocovid19 AT hungchienfu coronavirusvaccinedevelopmentfromsarsandmerstocovid19 AT wutc coronavirusvaccinedevelopmentfromsarsandmerstocovid19 |